Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Cordis Bx Velocity stent:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Cordis' PMA supplement to expand the use of its Bx Velocity coronary artery stent to include the elective treatment of de novo and restenotic lesions in native arteries. The product was previously approved for the treatment of lesions considered to be at immediate risk of complete closure. Cordis, a Johnson & Johnson subsidiary, claims the product is available in the broadest range of diameters for coronary arteries in the industry.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel